Monday, November 2, 2026
Two papers, a psychopharmacology pearl, a psychotherapy pearl and the news.
AI-generated content. This briefing was written by Claude Opus 5.5 and may contain errors. Please verify against the primary source before acting clinically.
| The Paper |
| New research from the psychiatric journals |
Clinical and genetic correlates of a circadian subtype of depression in the Australian Genetics of Depression Study
Tonini E, Crouse JJ, Shin M, Carpenter JS, Mitchell BL, et al.; Hickie IB. British Journal of Psychiatry. October 2026.
Using cross-sectional data from the nationwide Australian Genetics of Depression Study, the authors classified people with depression as having a 'circadian' subtype if they met at least three of six features: social jetlag, seasonality, delayed sleep midpoint, evening chronotype, morning tiredness, and hypersomnia. They then compared clinical course, self-reported antidepressant response, and polygenic risk scores between groups.
About 23 percent (2,604 participants) met criteria. Compared with the non-circadian group, they had an earlier age at onset, more (hypo)manic-like and psychotic-like experiences, more suicidality and somatic complaints, and weight gain during episodes. They reported poorer response to SSRIs (OR 0.88) and SNRIs (OR 0.89) with more side effects, and carried higher polygenic risk for ADHD, bipolar disorder, BMI, triglycerides, IL-6, insulin resistance, and later sleep timing.
|
In practice
A late-chronotype, hypersomnic, seasonal depression with early onset is a profile to recognize: it travels with bipolar-spectrum and metabolic liability and may respond less well to a first-line SSRI. Asking about sleep timing and chronotype belongs in the depression intake; note that response here was self-reported and the data are cross-sectional, so this is a signal for vigilance, not a prescribing rule. |
Full text doi:10.1192/bjp.2026.10798
| A Landmark |
| From 50 Studies Every Psychiatrist Should Know |
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. The Lancet. March 2000.
Prompted by concern that sudden unexplained deaths in psychiatric patients might be drug-induced arrhythmias, the Newcastle group recorded ECGs in 495 psychiatric inpatients and community patients and 101 healthy controls, measuring QTc with a validated digitiser technique. Using the control group to set the upper limit of normal, they defined abnormal QTc as more than 456 ms, which was present in 8 percent of patients (40 of 495).
In logistic regression, age over 65 (OR 3.0), tricyclic antidepressants (OR 4.4), thioridazine (OR 5.4) and droperidol (OR 6.7) independently predicted QTc lengthening, and so did antipsychotic dose, with odds rising from high (OR 5.3) to very high doses (OR 8.2). QT dispersion and T-wave abnormalities were not linked to antipsychotics but were associated with lithium.
|
In practice
This paper helped push thioridazine and droperidol into restricted, boxed-warning territory, and its core lesson still holds: antipsychotic QTc risk is agent-specific and dose-related, so the risk lives in the high-dose, polypharmacy, older patient rather than in the class as a whole. What has been refined since is the endpoint: later work tied antipsychotics to sudden cardiac death directly, and modern practice targets ECG monitoring at patients with added risk factors (age, electrolyte loss, cardiac disease, interacting drugs) rather than screening everyone. |
Full text doi:10.1016/s0140-6736(00)02035-3
| Past the Boards |
| One advanced clinical point, usually pharmacology |
VMAT2 inhibitors for tardive dyskinesia have a dose ceiling that the antidepressant sets
Valbenazine and deutetrabenazine are both converted to active dihydrotetrabenazine metabolites whose clearance depends in part on CYP2D6, so exposure rises when a strong 2D6 inhibitor is on board. That matters in psychiatry because the patient with tardive dyskinesia is very often also taking fluoxetine, paroxetine or bupropion.
The labels handle this differently. Deutetrabenazine is capped at 36 mg/day (no more than 18 mg per dose) with a strong CYP2D6 inhibitor, against a usual maximum of 48 mg. Valbenazine's label recommends the 40 mg dose with a strong CYP2D6 inhibitor, and also with a strong CYP3A4 inhibitor, because valbenazine itself is cleared by 3A4 as well.
The practical move: check the antidepressant before titrating, and if one of these inhibitors is started or stopped later, revisit the VMAT2 dose. Excess exposure shows up as sedation, parkinsonism and QT prolongation, so a patient whose TD improved but who now looks slowed down may simply be over-exposed.
| In the Room |
| A psychotherapy technique, shown in a vignette |
Containment means handing the feeling back digested, not returned unopened
Bion's idea of containment describes what the therapist does with a feeling the patient cannot yet bear and has, through projective identification, induced in the therapist. The contained affect is not simply named back to the patient ('you are making me feel helpless'), which returns it in the same raw form and usually lands as an accusation. Containment has three steps: tolerate the feeling without acting on it, think about what it tells you about the patient's inner experience, and only then offer a version the patient can take in, usually framed as something about the patient's state rather than your own. The test of whether you have contained rather than evacuated is tone: a contained intervention sounds curious and unhurried, while an uncontained one carries the urgency, irritation or despair the patient put into you. Often the first useful response is not an interpretation at all but staying steady in the session, which itself communicates that the feeling is survivable.
|
Vignette
A 34-year-old man, three months into weekly psychodynamic therapy, spends a session listing every failed treatment and ends with: 'So what's your plan? Because I'm out of ideas.' The resident notices a rising pull to propose a medication change and a feeling of sinking incompetence. The tempting response is to defend the treatment or to say 'it sounds like you want me to fix this.' Instead the resident waits, lets the helplessness register, and says: 'It sounds like you have been carrying the job of finding the answer alone for a long time, and it has become unbearable to keep failing at it.' The patient goes quiet, then talks for the first time about being his mother's only support as a child. The resident's helplessness was the patient's, held long enough to be put into words he could use. |
| *** |
| That's the five. Go see your first patient. |